The triple combination therapy group had higher rates of fever (47.4% vs. 23.7%, P=0.002), thrombocytopenia (61.8% vs. 35.5%, P=0.001), elevated ALT (69.7% vs. 32.9%, P<0.001), elevated AST (89.5% vs. 39.5%, P<0.001), hypoalbuminemia (89.5% vs. 53.9%, P<0.001), hyperbilirubinemia (55.3% vs. 17.1%, P<0.001), and the SC group had higher rates of fatigue (32.9% vs. 10.5%, P=0.001) and anemia (77.6% vs. 59.2%, P=0.015). The gene discussed is GPT; the disease is Thrombocytopenia.